Detection and Characteristic of Whipple Diseases in the Great Britany

Overview

Whipple's disease is a chronic systemic infection caused by ubiquitous bacterium Tropheryma wipplei on a genetic predisposition which should be considered in patients with recurrent episodes of seronegative arthritis, erosive or not, or inflammatory low back pain, chronic diarrhea, persistent fever, unexplained neurological signs, uveitis, endocarditis, and epithelioid granuloma. Laboratory tests may show malabsorption, erythrocyte sedimentation rate and C-reactive protein elevation, anemia, thrombocytosis, eosinophilia and lymphopenia. None of theses findings is specific and most patients have arthritis or low back pain mimicking rheumatoid arthritis and spondyloarthritis. As the disease is rare, chance for positive polymerase chain reaction testing for Tropheryma whipplei is low in this context.

Study Type

  • Study Type: Observational
  • Study Design
    • Time Perspective: Retrospective
  • Study Primary Completion Date: February 9, 2018

Arms, Groups and Cohorts

  • Classic Whipple’s disease (CWD)
    • Classic Whipple’s disease (CWD), defined as duodenal biopsy positive by PAS/immunohistochemistry or blood positive by PCR
  • Focal Whipple’s disease (FWD)
    • Focal Whipple’s disease (FWD), defined as joint fluid positive by PCR but duodenal biopsy negative by PAS/immunohistochemistry
  • Chronic T. whipplei-associated arthritis (CTWA)
    • Chronic T. whipplei-associated arthritis (CTWA) defined as chronic arthritis and duodenal biopsy, stool, or saliva positive by PCR duodenal biopsy negative by PAS/immunohistochemistry joint fluid negative by PCR

Clinical Trial Outcome Measures

Primary Measures

  • Number of patients diagnosed as whipple’s disease
    • Time Frame: Day 0 ( Date of diagnostic)
    • Diagnosis of Whipple’s disease based on at least one suggestive clinical finding at least one test detecting T. Whipplei diagnosis made by a specialist a dramatic and persistent response to antibiotic therapy Hydroxychloroquine 200mgx2 plus Doxycycline 100mgx2 or trimethoprim/sulfamethoxazole 800/160mg x2

Secondary Measures

  • Number of test performed in each centre
    • Time Frame: Day 0 (Date of diagnostic)
    • Number of diagnoses according to tests Patients will be divided into three groups Classic Whipple’s disease (CWD), defined as : duodenal biopsy positive by PAS/immunohistochemistry or blood positive by PCR Focal Whipple’s disease (FWD) joint fluid positive by PCR but duodenal biopsy negative by PAS/immunohistochemistry Chronic T. whipplei-associated arthritis (CTWA): chronic arthritis and duodenal biopsy, stool, or saliva positive by PCR duodenal biopsy negative by PAS/immunohistochemistry joint fluid negative by PCR

Participating in This Clinical Trial

Inclusion Criteria

  • Adult – patient with at least a screening test for Whipple'disease – participation agreement, Exclusion Criteria:
  • No test for Whipple'disease
  • Gender Eligibility: All

    Minimum Age: 18 Years

    Maximum Age: N/A

    Are Healthy Volunteers Accepted: No

    Investigator Details

    • Lead Sponsor
      • University Hospital, Brest
    • Provider of Information About this Clinical Study
      • Sponsor

    Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

    At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.